Innovative solutions for new methods of wound healing are to be developed. The three partners EVOMEDIS GmbH,the Medical University of Graz and JOANNEUM RESEARCH COREMEDare committed to this mission. One of these innovations is EVOCellic, a cell therapy for the treatment of burns and chronic wounds. With EVOCellic, cell-based therapy is possible exactly when patients need it. Waiting times can also be avoided. EVOMEDIS has pledged an investment of 1.5 million euros over a period of two years for the development of this innovation.
What does cell-based therapy (EVOCellic) mean?
EVOCellic is a keratinocyte (skin cell) based skin substitute made from allogeneic (not harvested from patients) cells. When applied to a wound, EVOCellic enables fast and effective healing by stimulating the skin's natural regeneration process through the release of growth factors. The European Medicines Agency has granted it orphan drug designation (EU/3/22/2637) for the treatment of partial-thickness burns of the deep dermis and the entire skin.
The co-operation
This partnership between the research institutions serves to deepen the existing collaboration. As part of the scientific collaboration, EVOCellic will undergo further optimisation of the production process and the necessary preclinical tests by a team led by Lars-Peter Kamolz, Director of COREMED and Chairman of the Department of Surgery. The next stage of GMP production customisation will be carried out in the GMP facility for new cell therapeutics (ATMPs) at MedUni's Division of Blood Group Serology and Transfusion Medicine under the direction of Peter Schlenke, Head of the Department of Blood Group Serology and Transfusion Medicine.
